News

FDA priority review status is granted to therapies that offer major advances in treatment or provide a treatment where no adequate therapy exists. This status accelerates the standard

In the study, 1,000 healthy volunteers aged 18 to 64 years old were enrolled to receive two doses of 5mcg, 15mcg or 45mcg of Novavax’s 2009 H1N1 influenza

Horizant is an investigational treatment for moderate-to-severe primary Restless Legs Syndrome developed by Xenoport and licensed to GlaxoSmithKline. Depomed noted that unlike Horizant, its proprietary extended release formulations

Lapatinib, in combination with an aromatase inhibitor (AI), is indicated for the treatment of post-menopausal women with hormone receptor (HR)-positive, HER2 (ErbB2) over-expressing metastatic breast cancer. The patients

StromaCel is the fifth subsidiary of Proteonomix, whose operating subsidiary is National Stem Cell. Its subsidiary is The Sperm Bank of New York, which is engaged in reproductive

The RNA control kits, manufactured under cGMP, will enable Affymetrix to deliver a complete solution to its molecular diagnostic partners. The products will be configured for use with

EMB will acquire a license from Lonza on two key products: the Lonza Development Microreactor (process development) and Lonza Advanced Production Microreactors (manufacturing). As a result, EMB will

According to the terms of the deal, Natac, through its subsidiary Natac Research, has consented to offer the services of senior research scientists and the associated laboratory facilities,

Cilag International has given Basilea Pharmaceutica a notice of termination of the worldwide license, development and co-promotion agreement between the parties. The compound, including pending applications and in-market